Humacyte Inc (HUMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Humacyte Inc (HUMA) Earnings: Report Dates and Results
Humacyte (HUMA) is expected to report earnings on Mar 25, 2027. In the quarter ended Sep 30, 2026, Humacyte reported EPS of -$0.07, above the -$0.09 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HUMA has an expected report date of Mar 25, 2027.
HUMA Earnings Call
The latest HUMA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, HUMA beat 11, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.03M, up 36.8% from $753000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | -$0.09 | -$0.10 - -$0.06 | +22.22% | Beat | N/A | 4 | 1 up, 1 down | Nov 10, 2026 | $1.03M |
| Jun 30, 2026 | -$0.16 | -$0.10 | -$0.12 - -$0.09 | -60.00% | Miss | N/A | 3 | 2 up, 0 down | Aug 12, 2026 | $406000 |
| Mar 31, 2026 | -$0.09 | -$0.11 | -$0.13 - -$0.10 | +18.18% | Beat | -132.1% | 4 | 1 up, 0 down | May 13, 2026 | $495000 |
| Dec 31, 2025 | -$0.19 | -$0.13 | -$0.15 - -$0.13 | -46.42% | Miss | N/A | 3 | 1 up, 1 down | Mar 27, 2026 | $467000 |
| Sep 30, 2025 | -$0.11 | -$0.15 | -$0.18 - -$0.10 | +26.67% | Beat | N/A | 4 | 2 up, 0 down | Nov 12, 2025 | $753000 |
| Jun 30, 2025 | -$0.24 | -$0.18 | -$0.20 - -$0.16 | -33.33% | Miss | N/A | 3 | 1 up, 1 down | Aug 11, 2025 | $301000 |
| Mar 31, 2025 | $0.28 | -$0.21 | -$0.26 - -$0.15 | +233.33% | Beat | N/A | 4 | 1 up, 0 down | May 13, 2025 | $517000 |
| Dec 31, 2024 | -$0.21 | -$0.26 | -$0.30 - -$0.22 | +18.00% | Beat | N/A | 4 | 0 up, 1 down | Mar 28, 2025 | $7.23M |
| Sep 30, 2024 | -$0.26 | -$0.24 | -$0.26 - -$0.23 | -8.33% | Miss | N/A | 7 | 0 up, 0 down | Nov 8, 2024 | N/A |
| Jun 30, 2024 | -$0.48 | -$0.24 | -$0.25 - -$0.23 | -100.00% | Miss | N/A | 5 | 0 up, 0 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$0.25 | -$0.23 | -$0.24 - -$0.21 | -8.70% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2024 | N/A |
| Dec 31, 2023 | -$0.24 | -$0.24 | -$0.27 - -$0.20 | 0.00% | In line | N/A | 7 | 0 up, 0 down | Mar 22, 2024 | $10.79M |
| Sep 30, 2023 | -$0.24 | -$0.25 | -$0.27 - -$0.22 | +4.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.18 | -$0.22 | -$0.23 - -$0.21 | +18.18% | Beat | N/A | 6 | 0 up, 0 down | Aug 14, 2023 | N/A |
| Mar 31, 2023 | -$0.22 | -$0.21 | -$0.22 - -$0.20 | -4.76% | Miss | N/A | 5 | 0 up, 0 down | May 12, 2023 | N/A |
| Dec 31, 2022 | -$0.04 | -$0.23 | -$0.25 - -$0.22 | +82.61% | Beat | -109.8% | 6 | 0 up, 0 down | Mar 24, 2023 | N/A |
| Sep 30, 2022 | -$0.24 | -$0.22 | -$0.23 - -$0.19 | -9.09% | Miss | N/A | 6 | 0 up, 0 down | Nov 10, 2022 | $31000 |
| Jun 30, 2022 | -$0.19 | -$0.22 | -$0.23 - -$0.21 | +13.64% | Beat | N/A | 5 | 0 up, 0 down | Aug 12, 2022 | $1.30M |
| Mar 31, 2022 | -$0.22 | -$0.21 | -$0.22 - -$0.20 | -4.76% | Miss | N/A | 6 | 0 up, 0 down | May 13, 2022 | $233000 |
| Dec 31, 2021 | $0.41 | -$0.20 | -$0.22 - -$0.18 | +305.00% | Beat | N/A | 6 | N/A | Mar 29, 2022 | $177000 |
| Sep 30, 2021 | -$0.50 | -$0.21 | -$0.23 - -$0.18 | -138.10% | Miss | N/A | 6 | N/A | Nov 12, 2021 | $241000 |
| Jun 30, 2021 | -$0.76 | -$0.56 | -$0.95 - -$0.18 | -35.71% | Miss | N/A | 2 | N/A | Aug 16, 2021 | $690000 |
| Mar 31, 2021 | -$0.20 | -$0.90 | N/A | +77.78% | Beat | N/A | N/A | N/A | May 17, 2021 | $155000 |
| Dec 31, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 16, 2021 | $124000 |
| Sep 30, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Nov 12, 2020 | $914000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.26, after -$1.20 the year before. It was -$0.01 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.26 | N/A |
| Dec 31, 2024 | -$1.20 | N/A |
| Dec 31, 2023 | -$0.88 | N/A |
| Dec 31, 2022 | -$0.69 | N/A |
| Dec 31, 2021 | -$1.05 | N/A |
| Dec 31, 2020 | -$0.01 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,745 | 10 | |
| 2026Q2 | Jun 30, 2026 | 4,823 | 9 | |
| 2026Q1 | Mar 31, 2026 | 4,975 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,627 | 10 | |
| 2025Q2 | Jun 30, 2025 | 4,987 | 9 | |
| 2025Q1 | Mar 31, 2025 | 5,229 | 9 | |
| 2024Q4 | Dec 31, 2024 | 6,296 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,563 | 9 |
2026Q3 Earnings Call
Opening remarks
Thomas Johnson LifeSci Advisors Representative Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which, after filing, may be accessed from the Investor page of the Humacyte website. Joining me on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Jim Mercadante, Chief Commercial Officer; and Dale Sander, Chief Financial Officer and Chief Corporate Development Officer. Dr. Niklason will provide a summary of the company's progress for the third quarter and recent weeks. Jim will provide an update on the commercial transformation and progress with the Symvess market launch, and Dale Sander will review the company's financial results for the quarter ended September 30, 2026. I will now turn the call over to Dr. Niklason. Laura?
Laura Niklason President and Chief Executive Officer Thank you, Tom, and good morning, everyone. I want to thank you for joining us for our third quarter financial results and business update call. I could not be more excited to share the progress that we're making at Humacyte. What we're doing at Humacyte is exceptionally challenging, and we have created a first-in-class biologic solution that addresses some very significant and broad-based health problems. We have built a team of incredibly talented scientists and other professionals and an outstanding manufacturing facility. I wish that you all had the opportunity to come down and take a tour of our facility. Even representatives from much larger medical device and pharmaceutical organizations walk away in awe of what we have built. I believe that the momentum that we have demonstrated this quarter, along with the upcoming filings and clinical trials, has set the stage for a very significant value creation story in the months and years ahead. It's taken a lot of work to get to this point, and my sincere hope is that we will all look back on today's call as an inflection point for the company. On today's call, after my overview, we'll begin with Jim's review of our commercial progress for Symvess.
Frequently Asked Questions About HUMA
When is Humacyte's next earnings date?
Humacyte's next earnings report is expected for Mar 25, 2027.
Did HUMA beat earnings estimates last quarter?
Yes. Humacyte reported EPS of -$0.07 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 22.22% surprise.
What EPS do analysts expect from HUMA next quarter?
The consensus EPS estimate for Humacyte for the quarter ending Dec 31, 2026 is -$0.07 from 8 analysts, with estimates from -$0.11 to -$0.05.
How often does HUMA beat earnings estimates?
Humacyte beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +22.33%.
HUMA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors